Shares of MDA Space Ltd. tumbled nearly 21% over the past week, sliding from $56.32 to $44.68, as investors digested the company's plan to issue a wave of new stock to fund its roughly C$920 million acquisition of a 70% stake in CLS, a European Earth-observation and data analytics firm. The sell-off reflects a classic tension: a deal that could reshape MDA's business is being paid for by shrinking every existing shareholder's piece of the pie. MDA Space Floods the Market With New Stock to Chase a French Satellite Deal — Can the Strategy Justify the Pain?
Shares of MDA Space have shed more than 20% since July 7, dropping from $56.32 to $44.68, as investors absorb what amounts to one of the largest equity raises in the Canadian space sector's history. The company is printing millions of new shares to buy a majority stake in a French Earth-observation firm, and the market is making clear that the price of ambition is steep.
The Deal Got Bigger — and So Did the Dilution. MDA initially announced a bought-deal offering of 20 million shares at US$35.60 each for gross proceeds of US$712 million.
Just one day later, it upsized the deal to 23 million shares, lifting total gross proceeds to roughly US$819 million.
Underwriters also hold an option to buy an additional 15% of shares within 30 days — meaning up to 26.45 million new shares could ultimately hit the market. For existing holders, that's a significant chunk of ownership being given away, and the $35.60 offering price sits well below where the stock traded before the announcement.
A C$920 Million Bet on Earth-Observation Data. MDA is paying approximately €567 million (C$920 million) in cash for a 70% stake in CLS, a provider of AI-driven satellite data analytics with more than 14,000 customers across 150 countries and expected 2026 revenue of about C$465 million.
CLS has grown revenue at roughly 22% annually since 2023, and its profit margins align with MDA's own 18-to-20% target range. The strategic pitch: combining MDA's satellites with CLS's data processing to sell finished intelligence products rather than raw images.
Wall Street Likes the Vision but the Stock Says "Show Me." Twelve analysts rate MDA a consensus Strong Buy with an average price target of C$66.17.
JPMorgan initiated coverage with a US$34 target and an Overweight rating, projecting roughly 25% upside. Yet the stock keeps falling — a sign that institutional investors are recalculating earnings-per-share after the flood of new stock, and wondering whether CLS can deliver enough profit growth to offset the dilution.
A Structural Risk Lurks in the Fine Print. The offering and the acquisition are not conditional on each other — meaning MDA could raise the cash and still fail to close the deal if French regulatory approvals stall. If CLS cannot refinance its own €198 million in existing debt, MDA would need to cover that too.
Management says leverage will stay within 1.5 to 2.5 times net debt to adjusted EBITDA , but in a deal this complex, assumptions can shift fast.